TURNSTONE BIOLOGICS
Turnstone Biologics is a privately-held clinical-stage biotech company. Turnstone Biologics’ mission is to deliver breakthrough cancer immunotherapies by advancing two leading and complementary platforms targeting tumor immunity, to improve survival for people with cancer.
TURNSTONE BIOLOGICS
Industry:
Biotechnology Innovation Management Therapeutics
Founded:
2015-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.turnstonebio.com
Total Employee:
101+
Status:
Active
Contact:
(613)421-8930
Email Addresses:
[email protected]
Total Funding:
132.7 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API WordPress Google Analytics LetsEncrypt SSL By Default
Similar Organizations
ArsenalBio
ArsenalBio is a programmable cell therapy company that offers advanced CAR T-cell therapies for solid tumors.
C2N Diagnostics
C2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Oerth Bio
Oerth Bio is a agriculture-focused biotech firm.
Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical stage biotechnology company.
Singleron Biotechnologies
Singleron Biotechnologies is an innovative molecular diagnostic company.
Stemson Therapeutics
Stemson Therapeutics is a pre-clinical stage cell therapy company.
Sterna Biologicals
Sterna Biologicals GmbH & Co. KG is an innovative clinical-stage immunology.
IndieBio
IndieBio is the largest biotech startup accelerator, run by SOSV.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-01-20 | Myst Therapeutics | Myst Therapeutics acquired by Turnstone Biologics | N/A |
Investors List
Brace Pharma
Brace Pharma investment in Series D - Turnstone Biologics
Ridgeback Capital
Ridgeback Capital investment in Series D - Turnstone Biologics
PFM Health Sciences
PFM Health Sciences investment in Series D - Turnstone Biologics
Point72
Point72 investment in Series D - Turnstone Biologics
Northleaf Capital Partners
Northleaf Capital Partners investment in Series D - Turnstone Biologics
Surveyor Capital
Surveyor Capital investment in Series D - Turnstone Biologics
Sixty Degree Capital
Sixty Degree Capital investment in Series D - Turnstone Biologics
Teralys Capital
Teralys Capital investment in Series D - Turnstone Biologics
JM Family Enterprises
JM Family Enterprises investment in Series D - Turnstone Biologics
Versant Ventures
Versant Ventures investment in Series D - Turnstone Biologics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-02-20 | Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq. |
| 2022-04-19 | Turnstone Biologics Announces Executive Leadership Appointments |
Official Site Inspections
http://www.turnstonebio.com Semrush global rank: 10.01 M Semrush visits lastest month: 282
- Host name: 83.162.211.130.bc.googleusercontent.com
- IP address: 130.211.162.83
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Turnstone Biologics"
Turnstone Biologics - Crunchbase Company Profile & Funding
Organization. Turnstone Biologics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email …See details»
Turnstone Biologics - LinkedIn
Turnstone Biologics | 13,205 followers on LinkedIn. Developing next-generation TIL-based therapies to treat and cure solid tumors. | Turnstone Biologics is a clinical-stage biotechnology …See details»
Turnstone Biologics Appoints William Waddill to its Board of …
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a …See details»
Turnstone Biologics - Overview, News & Similar companies
Apr 16, 2024 Who is Turnstone Biologics. Turnstone is developing a disruptive class of engineered viral immunotherapies, attacking cancer's complexity with medicines designed to …See details»
Turnstone Biologics Announces Executive Leadership …
May 7, 2021 For more information, please visit www.turnstonebio.com, and follow Turnstone on LinkedIn. Contacts Turnstone Biologics Ahmed Aneizi 613-421-8930 [email protected]See details»
FACIT Startup Turnstone Biologics Closes $11M Financing, Secures ...
Oct 28, 2015 Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential TORONTO, Oct. 28, 2015 /CNW/ – Turnstone Biologics Inc. …See details»
Turnstone Biologics Enters Cooperative Research and …
Nov 29, 2022 For more information, please visit www.turnstonebio.com, and follow us on LinkedIn. Contacts. Ahmed Aneizi Turnstone Biologics (347) 897-5988 …See details»
Turnstone Biologics Acquires Novel Cell Therapy Platform
Jan 20, 2021 [email protected]. Contact Us. [email protected] (347) 897-5988. Subscribe to our Email Alerts. Get new updates directly to your inbox. SubmitSee details»
Turnstone Biologics Raises $80 Million Series D Financing
Jul 21, 2021 For more information, please visit www.turnstonebio.com, and follow Turnstone on LinkedIn. Contacts. Ahmed Aneizi Turnstone Biologics 613-421-8930 [email protected].See details»
FACIT Startup Turnstone Biologics Closes $11M Financing, Secures ...
Turnstone Biologics Inc. (“Turnstone” or the “Company”), a FACIT-incubated startup, has completed its $11.3 million Series A financing round led by Versant Ventures (“Versant”) with …See details»
TBio BFX 4101 – A Neoantigen Prioritization Pipeline ... - Turnstone …
TBio BFX 4101 – A Neoantigen Prioritization Pipeline for Selected Tumor-Infiltrating Lymphocyte TherapySee details»
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year …
Mar 21, 2024 Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone’s novel Selected TIL …See details»
Turnstone Biologics and the La Jolla Institute for Immunology …
Sep 4, 2018 Turnstone Planning to Initiate Phase I/II Clinical Trial Utilizing Personalized Neoantigen Therapy with Proprietary MG1 Viral Platform in 2019 NEW YORK and LA JOLLA, …See details»
Turnstone Biologics Announces TIL Therapy Research …
Apr 25, 2022 Ahmed Aneizi Turnstone Biologics 613-421-8930 [email protected]. Release Summary.See details»
Turnstone Biologics to Present Preclinical Data From Novel TIL …
For more information, please visit www.turnstonebio.com, and follow us on LinkedIn. Contacts. Ahmed Aneizi Turnstone Biologics (347) 897-5988 [email protected]. Contact …See details»
Turnstone Biologics Corp. (TSBX) - Yahoo Finance Canada
Find the latest Turnstone Biologics Corp. (TSBX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Turnstone Biologics Acquires Novel Cell Therapy Platform
Jan 20, 2021 For more information, please visit www.turnstonebio.com, and follow Turnstone on LinkedIn. Contacts. Turnstone Biologics Ahmed Aneizi 613-421-8930 …See details»
Tumor-Infiltrating Lymphocyte Treatment for Anti-PD-1-Resistant ...
Tumor-Infiltrating Lymphocyte Treatment for Anti-PD-1-Resistant Metastatic Lung Cancer: A Phase 1 Trial. Benjamin C. Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza ...See details»